A class action lawsuit has been initiated against Mereo BioPharma Group plc, alleging the company made materially false and misleading statements regarding its clinical development programs. The litigation centers on the company's Phase 3 ORBIT and COSMIC trials, which both failed to achieve their primary endpoints, raising questions about the adequacy and timeliness of disclosures made to investors.
The lawsuit encompasses investors who purchased Mereo securities during a specific window, from June 5, 2023 through December 26, 2025. This period captures the timeframe when investors may have relied on representations about the clinical programs before the trial failures became public knowledge. The scope of affected shareholders underscores the potential market impact of the undisclosed trial results.
Investors seeking to participate in the litigation must meet certain eligibility requirements, with a lead plaintiff deadline established for April 6, 2026. This timeline allows interested parties to evaluate their potential involvement in the case while establishing the procedural framework for the lawsuit's progression. The litigation represents a significant development for Mereo shareholders concerned about investment losses.